News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

IntelligentMDx to Present Development of Two CE-Marked Assays at 22nd Annual European Congress of Clinical Microbiology and Infectious Diseases


3/27/2012 2:16:11 PM

March 27, 2012, Cambridge, MA – IntelligentMDx (IMDx), a molecular diagnostic company that uses a proprietary bioinformatics platform that accelerates the development of PCR-based diagnostic testing solutions, will be presenting three posters at the 22nd annual European Congress of Clinical Microbiology and Infectious Diseases Meeting (ECCMID). The ECCMID meeting on March 31 – April 3, 2012 in London, UK, attracts more than 7,000 participants with expertise in infectious disease areas, including emerging infections, diagnosis, prevention, and treatment.

IMDx has designed, developed, and manufactured two CE-marked assays in the past year under a multi-year distribution agreement with Abbott. One CE-marked assay provides rapid and sensitive detection of toxigenic Clostridium difficile, while the second CE-marked assay provides for the detection of Vancomycin-resistant Enterococci. A third assay will be CE-marked later this year for the detection of Group B streptococcus. All three assays have been designed and validated to run on the Abbott m2000™ system, for fully automated, high-throughput diagnosis of these infectious diseases. The IMDx pipeline includes assays for detection of Herpes Simplex Virus 1 and 2, Influenza A/B and RSV, Epstein-Barr virus, BK virus, and additional assays targeting oncology, human genetics and companion diagnostics.

The three posters presented by Dr. Heinz Reiske, Manager of Research and Development at IMDx, will detail the technology used to develop the IMDx assays and present performance characteristics for each assay.

To view IMDx Posters at ECCMID, please visit:

Sunday, April 01, 2012, Poster Session III, 13:30 - 14:30, Spot P1381

Development of a high-throughput, rapid and sensitive molecular assay on the Abbott m2000 for detection of group B Streptococcus in antepartum and intrapartum women

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

Monday, April 02, 2012, Poster Session IV, 12:30 - 13:30, Spot P1659

A CE-marked automated molecular test on the Abbott m2000 for the detection of vancomycin resistance genes vanA and vanB most commonly found in vancomycin-resistant enterococci

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

Tuesday, April 03, 2012, Poster Session VI, 12:30 - 13:30, P 2268

A CE-marked DNA molecular assay on the Abbott m2000 for the detection of toxigenic and hypervirulent strains of C. difficile

H. Reiske*, C. Leslin, R. Kowal, A. Jacobs, R. Del Mastro (Cambridge, Des Plaines, US)

* These products are intended for CE-marking and are not available for sale in the United States.

About IMDx

Based in Cambridge, MA, IMDx (www.IntelligentMDx.com) is an innovative company that designs, develops and manufactures molecular diagnostic products. IMDx has developed molecular solutions that are clinically impactful and competitively differentiated for a range of disease areas for current and next generation systems, including targets in infectious diseases, oncology and genetics. IMDx's expertise spans evolutionary biology, bioinformatics, microbiology, chemistry and molecular biology. These capabilities are harnessed by IMDx's proprietary bioinformatics and product development processes allowing for the rapid design and development of tests to meet clinical needs.


Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES